219 related articles for article (PubMed ID: 16396760)
21. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
22. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
23. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
24. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.
Thiele J; Kvasnicka HM; Fischer R
Ann Hematol; 1999 Nov; 78(11):495-506. PubMed ID: 10602893
[TBL] [Abstract][Full Text] [Related]
25. The histopathology of chronic myeloproliferative diseases.
Georgii A; Buesche G; Kreft A
Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
[TBL] [Abstract][Full Text] [Related]
26. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond.
Michiels JJ
Hematology; 2005; 10 Suppl 1():215-23. PubMed ID: 16188676
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.
Thiele J; Kvasnicka HM
Semin Thromb Hemost; 2006 Apr; 32(3):219-30. PubMed ID: 16673276
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
Macdonald D; Cross NC
Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
[TBL] [Abstract][Full Text] [Related]
29. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
31. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
Bartl R; Frisch B; Wilmanns W
Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
[TBL] [Abstract][Full Text] [Related]
32. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
33. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathology and histochemistry on bone marrow biopsies in chronic myeloproliferative disorders--a clue to diagnosis and classification.
Thiele J; Kvasnicka HM
Pathol Biol (Paris); 2001 Mar; 49(2):140-7. PubMed ID: 11317959
[TBL] [Abstract][Full Text] [Related]
35. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
36. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
[TBL] [Abstract][Full Text] [Related]
37. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Hyun BH; Gulati GL; Ashton JK
Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176
[TBL] [Abstract][Full Text] [Related]
38. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
Thiele J; Kvasnicka HM
Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
[TBL] [Abstract][Full Text] [Related]
39. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
40. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]